Photoactive platinum(II) azopyridine complexes by Farley, Sarah J. et al.
Photochemistry and Photobiology, 20**, **: *–*
Special Issue Research Article
Photoactive Platinum(II) Azopyridine Complexes†
Sarah J. Farley1 , Luca Salassa1,2,3,4* , Ana M. Pizarro1,5 and Peter J. Sadler1*
1Department of Chemistry, University of Warwick, Coventry, UK
2Donostia International Physics Center, Donostia, Spain
3Polimero eta Material Aurreratuak: Fisika, Kimika eta Teknologia, Kimika Fakultatea, Euskal Herriko Unibertsitatea UPV/
EHU, Donostia, Spain
4Ikerbasque, Basque Foundation for Science, Bilbao, Spain
5IMDEA Nanociencia, Madrid, Spain
Received 13 January 2021, revised 14 February 2021, accepted 18 February 2021, DOI: 10.1111/php.13405
ABSTRACT
Platinum(II) complexes containing the strong p-acceptor N,N-
chelating ligand phenylazopyridine (Ph-azpy) [Pt(p-R-Ph-
azpy)X2], R = H, NMe2 or OH, X = Cl or N3, have been syn-
thesized and characterized to explore the effects of monoden-
tate ligands and phenyl substituents on their absorption
spectra and photoactivation. Time-dependent density func-
tional theory calculations showed that the complexes have a
low-lying unoccupied orbital with strong r-antibonding char-
acter toward the majority of the coordination bonds. The
UV–visible absorption bands were assigned as mainly ligand-
centered or metal-to-ligand charge-transfer transitions, with
strong contributions from the chlorido and azido groups. In
complexes with substituted Ph-azpy ligands, r-donation from
NMe2 and OH/O
– groups results in a redshift of the main
absorption bands compared with unsubstituted Ph-azpy com-
plexes. The diazido complexes are photoactive in solution
upon irradiation with either UVA or visible light for R = H
or NMe2, or UVA only when R = OH/O
–. Intriguingly, the
phenolate group of the latter complex undergoes very slow
protonation in solution. Biological screening was limited by
poor solubility; however, initial tests showed that the pheno-
lato diazido complex is rapidly taken up into the nuclei of
HaCaT keratinocytes, which are stained intensely blue, and
its cytotoxicity is increased upon irradiation with UVA light.
INTRODUCTION
There is current interest in the design of photoactivatable metal
complexes for use in phototherapy (1–4). Two such complexes
that recently entered clinical use are the Ru(II) complex TLD-
1433 and the Pd(II) complex TOOKAD Soluble. In particular,
it is desirable to be able to tune the wavelength of absorption
and photoactivation to match the desired penetration depth of the
irradiation, ranging from UVA and blue light to the longer depth
of penetration of red and near-IR radiation.
Among the most widely used anticancer drugs are Pt(II) com-
plexes, including cisplatin, carboplatin and oxaliplatin. However,
there is a need to overcome emerging resistance to these drugs
as well as the side effects associated with their use. One potential
approach could involve the administration of platinum complexes
with low toxicity as inactive prodrugs, which could then be acti-
vated specifically in tumors using directed photoirradiation. Octa-
hedral diazido diamine Pt(IV) complexes are promising for such
purposes (5–7). Here, we explore the properties of square-planar
Pt(II) diazido complexes containing the strong p-acceptor ligand
phenylazopyridine, with the aim of generating complexes that
absorb strongly in the visible region.
The use of azopyridines as ligands introduces several interest-
ing features into metal complexes. First, they often reduce the
reactivity of the coordinated metal. For example, Ru(II) and Os
(II) arene, and Ir(III) Cp* anticancer complexes that contain
azopyridine ligands can be quite inert toward ligand substitution
reactions such as aquation. They are activated in cells by attack
of the intracellular thiol glutathione on the azo double bond (8–
10). Second, they can introduce intense metal-to-ligand charge
transfer (MLCT) and intraligand p–p* transitions into the metal
complex, giving rise to strong visible light absorption and
intense colors (11). Third, UVA irradiation can induce trans–cis
isomerization of the N=N bond in monodentate (pyridine N-
bound) ligands, for example in organo-Pt(II) complexes.
One of the few reports of the use of azopyridine ligands in
the design of photoactivatable platinum complexes is that of
Chakravarty et al. (12). Among the complexes studied was [Pt
(Ph-azpy)(an-cat)], where H2an-cat is 4-[2-[(anthracen-9-yl-
methylene)amino]ethyl]benzene-1,2-diol, a catechol ligand conju-
gated to anthracene as a photosensitizer. This complex exhibited
a broad charge-transfer band at around 750 nm involving the
coordinated catecholate ligand, and photocytoxicity toward
HaCaT human skin keratinocytes and MCF-7 breast cancer cells
upon irradiation with visible light.
Here, we explore a different approach to controlling the UV–
visible absorption of Pt(II) phenylazopyridine complexes by
varying the monodentate ligands and the substituents on the
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phenyl ring to prepare six square-planar complexes, [Pt(p-R-Ph-
azpy)X2], R = H, NMe2 or OH, X = Cl or N3, as illustrated in
Fig. 1. We show that both the monodentate ligands and the phe-
nyl substituents can have significant effects on the absorption
spectra and photoactivity. We use time-dependent density func-
tional theory (TD-DFT) calculations to assign the transitions and
identify the frontier orbitals, and the solution chemistry of the
complexes is investigated. Attempts to explore the suitability of
these complexes as photoactivatable platinum anticancer pro-
drugs were limited by their poor solubility in aqueous media,
with the exception of the phenolate diazido complex 6, which
showed interesting behavior in aqueous solution and was
screened for photocytotoxicity toward immortalized human ker-
atinocytes.
MATERIALS AND METHODS
Materials. 2-(Phenylazo)pyridine (Ph-azpy) and 4-(2-pyridylazo)phenol
(HO-Ph-azpy) were kindly donated by Dr Sarah Dougan, and were
synthesized as previously described (13). The former was purified by
column chromatography prior to use (silica gel, eluting with 100%
dichloromethane), whereas the latter was used as received. 4-(2-Pyridylazo)-
N,N-dimethylaniline (Me2N-Ph-azpy) was purchased from Sigma-Aldrich,
and cis-[Pt(DMSO)2Cl2] was synthesized as reported (14). UV-grade
dioxane (Sigma-Aldrich) and HPLC-grade methanol and water (Fisher)
were used as solvents for UV–visible spectroscopy. All other reagents
were obtained from commercial sources and were used as received.
Synthesis of Pt(II) azopyridine complexes. [Pt(Ph-azpy)Cl2] (1), Ph-
azpy (75 mg, 0.41 mmol) was dissolved in dichloromethane (5 mL) and
added to a solution of cis-[Pt(DMSO)2Cl2] (174 mg, 0.41 mmol) in
dichloromethane (30 mL). After 5 min, the orange solution began to
darken and was then stirred at room temperature for 4 h. The solvent
volume was reduced, and the mixture stored overnight at 277 K. A
brick-red solid was filtered off, washed with dichloromethane and dried
under vacuum.
Yield: 165 mg (90%). Elemental analysis: Found: C, 29.36; H, 1.86;
N, 9.12. PtC11H9N3Cl2 requires: C, 29.41; H, 2.02; N, 9.35%.
1H NMR
(500 MHz, CDCl3): d = 9.89 (d,
3J(195Pt–1H) 30 Hz, 1H), 8.56 (d, 1H),
8.39 (td, 1H), 7.99 (m, 3H), 7.61 (t, 1H), 7.55 ppm (t, 2H). ESI-MS:
471.97 [M + Na]+, NaPtC11H9N3Cl2 requires 471.97 m/z.
[Pt(Ph-azpy)(N3)2] (2), [Pt(Ph-azpy)Cl2] (1) (75 mg, 0.17 mmol) was
dissolved in dimethylformamide (10 mL), and the mixture was sonicated
to ensure dissolution. To this, a solution of NaN3 (109 mg, 1.7 mmol) in
methanol (6.5 mL) was added, upon which there was an immediate color
change from orange to deep pink. The solution was stirred in the dark at
room temperature for 48 h, after which all solvent was removed by rotary
evaporation. Water (5 mL) was added to dissolve any excess NaN3, and
the insoluble black product was filtered off, washed with small quantities
of water, ethanol and diethyl ether, and dried under vacuum.
Yield: 66 mg (85%). Elemental analysis: Found: C, 28.01; H, 1.82;
N, 26.50. PtC11H9N9 requires: C, 28.58; H, 1.96; N, 27.27%.
1H NMR
(500 MHz, CDCl3): d = 9.21 (d,
3J(195Pt–1H) 27 Hz, 1H), 8.48 (d, 1H),
8.34 (td, 1H), 8.05 (d, 2H), 7.94 (t, 1H), 7.65 (t, 1H), 7.58 ppm (t, 2H).
ESI-MS: 485.05 [M + Na]+, NaPtC11H9N9 requires 485.05 m/z.
[Pt(Me2N-Ph-azpy)Cl2] (3), Me2N-Ph-azpy (100 mg, 0.44 mmol) was
dissolved in dichloromethane (20 mL) and added to a solution of cis-[Pt
(DMSO)2Cl2] (185 mg, 0.44 mmol) in dichloromethane (55 mL). Upon
mixing, a color change from orange to blue was observed; the solution
was then stirred at room temperature for 4 h. The solvent volume was
reduced, and the mixture stored overnight at 277 K. A green-gold solid
was filtered off, washed with dichloromethane and dried under vacuum.
Yield: 195 mg (90%). Elemental analysis: Found: C, 31.62; H, 2.79; N,
11.28. PtC13H14N4Cl2 requires: C, 31.72; H, 2.87; N, 11.38%.
1H NMR
(500 MHz, CDCl3): d = 9.62 (d,
3J(195Pt–1H) 30 Hz, 1H), 8.39 (d, 2H),
8.15 (td, 1H), 8.08 (d, 1H), 7.57 (t, 1H), 6.74 (t, 2H), 3.22 ppm (s, 6H).
ESI-MS: 498.09 [M  Cl +MeCN]+, PtC15H17N5Cl requires 497.90 m/z.
[Pt(Me2N-Ph-azpy)(N3)2] (4), [Pt(Me2N-Ph-azpy)Cl2] (3) (25 mg,
0.05 mmol) was dissolved in dimethylformamide (5 mL) to give a blue
solution. NaN3 (33 mg, 0.51 mmol) in methanol (2 mL) was added; no
color change was observed. The solution was stirred in the dark at room
temperature for 48 h; then, water (100 mL) was added and the solution
lyophilized. To the residue, water (5 mL) was added to dissolve any
excess NaN3, and the insoluble green solid was filtered off, washed with
small quantities of water, ethanol and diethyl ether, and dried under vac-
uum. Yield: 19 mg (75%). Elemental analysis: Found: C, 30.79; H, 2.74;
N, 27.42. PtC13H14N10 requires: C, 30.89; H, 2.79; N, 27.71%.
1H NMR
(500 MHz, CDCl3): d = 9.01 (d,
3J(195Pt–1H) 32 Hz, 1H), 8.47 (d, 2H),
8.12 (t, 1H), 8.02 (d, 1H), 7.54 (t, 1H), 6.78 (t, 2H), 3.24 ppm (s, 6H).
ESI-MS: 528.09 [M + Na]+, NaPtC13H14N10 requires 528.09 m/z.
[Pt(HO-Ph-azpy)Cl2] (5), HO-Ph-azpy (56 mg, 0.28 mmol) was dis-
solved in methanol (50 mL) and added to a solution of cis-[Pt
(DMSO)2Cl2] (100 mg, 0.24 mmol) in methanol (100 mL). The mixture
was sonicated for five minutes to aid dissolution of the starting materials,
during which time it began to darken from orange to a deep red-brown
color. It was then stirred overnight at room temperature. The volume was
reduced, and the mixture stored at 277 K for 4 h. A brown solid was fil-
tered off, washed with methanol and collected. To ensure total removal
of cis-[Pt(DMSO)2Cl2], dichloromethane (8 mL) was added and the mix-
ture stirred, sonicated for 10 s, then filtered off and collected again.
Yield: 79 mg (68%). Elemental analysis: Found: C, 27.81; H, 2.15; N,
8.82. PtC11H9N3Cl2O requires: C, 28.40; H, 1.95; N, 9.03%.
1H NMR
(400 MHz, d4-MeOD): 9.60 (d,
3J(195Pt–1H) 32 Hz, 1H), 8.59 (d, 1H),
8.48 (td, 1H), 8.03 (d, 2H), 8.00 (t, 1H), 6.91 ppm (t, 2H). ESI-MS:
487.96 [M + Na]+, NaPtC11H9N3Cl2O requires 486.97 m/z.
Na[Pt(O-Ph-azpy)(N3)2] (6), [Pt(HO-Ph-azpy)Cl2] (5) (25 mg,
0.05 mmol) was dissolved in dimethylformamide (5 mL) to give a dark
orange solution. NaN3 (35 mg, 0.54 mmol) in methanol (2 mL) was
added; there was an immediate color change to deep blue. The solution
was stirred in the dark at room temperature for 48 h; then, water
(100 mL) was added and the solution lyophilized. To the residue, water
(5 mL) was added to dissolve any excess NaN3; the product was also
partially soluble; however, a quantity of dark blue product was isolated
and washed with small quantities of water, ethanol and diethyl ether, and
dried under vacuum. Yield: 18 mg (65%). Elemental analysis: Found: C,
26.61; H, 1.79; N, 23.95. PtC11H8N9ONa requires: C, 26.41; H, 1.61; N,
25.20%. 1H NMR (500 MHz, CDCl3): d = 8.63 (d,
3J(195Pt–1H) 32 Hz,
1H), 8.46 (d, 2H), 8.05 (t, 1H), 7.76 (d, 1H), 7.30 (t, 1H), 6.49 ppm (d,
2H). ESI-MS: 501.04 [M + H]+, NaPtC11H9N9O requires 501.04 m/z.
Note on CHN analyses: in our experience, the CHN analyses of azido
platinum complexes often suffer from problems with combustion, and
can give rise to larger deviations from expected values than are normally
found for high-purity compounds. For the present compounds, such devi-
ations are apparent for complex 2 (C 0.57%, N 0.77%), complex 5 (C
0.59%) and complex 6 (N 1.25%). However, their other CHN data, and
NMR and MS data are consistent with the expected compositions.
Mass spectrometry. Electrospray ionization mass spectra were
obtained either on a Bruker Esquire2000 Spectrometer or on a Bruker
MicroTOF Spectrometer. Samples were prepared either in water or in a
methanol/water mixture, and the cone voltage and source temperature
varied depending upon the sample. Data were processed using
DataAnalysis 3.3 (Bruker Daltonics).
NMR spectroscopy. NMR spectra were recorded on Bruker DPX
400 MHz (for 1H ), AV 400 MHz or DRX 500 MHz spectrometers. 1D
and 2D spectra were recorded using standard Bruker pulse sequences
modified by Dr Adam Clarke or Dr Ivan Prokes (University of
Figure 1. Structures of the Pt(II) azopyridine complexes studied in this
work.
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Warwick). Unless otherwise stated, spectra were acquired in 5 mm quartz
NMR tubes at 298 K. 1H chemical shifts (d, ppm) were referenced to
residual protio-solvent resonances: 7.26 (d1-chloroform), 3.31 (d4-
methanol) and 2.09 (d6-acetone). Spectral data were processed using
either XWIN-NMR (version 2.0 or 3.6, Bruker UK Ltd) or MestReC
(version 4.9.9.9, Mestrelab Research, Spain).
Computational methods. DFT calculations on the azopyridine ligands
and platinum complexes were carried out using Gaussian 03 (15).
Geometry optimization of the ground state was performed in the gas
phase with the gradient-corrected correlation functional PBE1PBE (16).
The LanL2DZ basis set (17) and effective core potential were used for
the Pt atom, and the 6–31G** basis set (18) was used for all other
atoms. Ligands were optimized at the PBE1PBE/6–31G** level. The
nature of all stationary points was confirmed by performing a normal-
mode analysis.
Sixteen singlet excited states for the ligands and thirty-two for the
complexes were calculated with TD-DFT (19) using ground-state geome-
tries optimized in the gas phase. The conductor-like polarizable contin-
uum model method (CPCM) (20) with methanol as solvent was used to
calculate the electronic structures and excited states in solution. The elec-
tronic distribution and the localization of the singlet excited states were
visualized using the electron density difference maps (EDDMs) (21).
GaussSum 1.05 (22) was used for calculation of the EDDMs and for sim-
ulation of the electronic spectra.
Kinetic studies of azopyridine ligands and Pt(II) complexes by UV–
visible spectroscopy. The UV–visible absorption spectra of the ligands
Ph-azpy, Me2N-Ph-azpy and HO-Ph-azpy, as well as the complexes 1–6,
were monitored over a 12 h period in dioxane at 298 K. Sample
preparation, carried out under subdued laboratory light, involved
dissolution of the compound in dioxane, filtration, appropriate dilution
and, where necessary, addition of acid. To allow for this, a delay of five
minutes was set between dissolution and recording the first spectrum.
Spectra were subsequently recorded every 2 min for 1 h, every 5 min for
a further 1 h, every 10 min for 3 h, then every 30 min for the remaining
7 h. In the case of HO-Ph-azpy and [Pt(HO-Ph-azpy)Cl2] (5), 10 lL (~3
equiv.) of 0.01 M HNO3 was added to ensure that the phenolic group
remained protonated. For Na[Pt(O-Ph-azpy)(N3)2] (6), the study was
carried out in methanol owing to the insolubility of the complex in
dioxane.
Stability of complex 6 in aqueous solution and cell culture medium.
The stability of complex 6 in aqueous solution was monitored at
310 K over a 12 h period by UV–visible spectroscopy. Following
dissolution of 6, spectra were recorded every 2 min for 1 h, every
5 min for a further 1 h, every 10 min for 3 h, then every 15 min for
the remaining 7 h. The stability of this complex was also assessed
under solution conditions similar to those used in cytotoxicity testing.
Following dissolution of the complex in DMSO, appropriate dilutions
were performed so that the final solution comprised 1% DMSO,
12.5% saline (0.9% NaCl solution) and 86.5% RPMI-1640 medium.
Because the medium is pink in color, a solution of the same
composition but without complex was used as a baseline for the UV–
visible absorption spectra, so that any absorbance observed was solely
from the complex.
Stability of Pt(II) complexes in acetone. The stability of complexes 1–
6 was monitored over time by 1H NMR spectroscopy. Saturated
solutions of the complexes were prepared in d6-acetone and a spectrum
was recorded immediately after dissolution (~5 min); spectra were then
re-recorded after 1, 3, 6, 18 and 113 days. Samples were stored at
ambient temperature in the dark between measurements.
Photoreactions. Photoreactions of complexes 1–5 in dioxane, and
complex 6 in methanol, were monitored by UV–visible spectroscopy. For
all complexes, irradiations were performed using an LZC-ICH2
photoreactor equipped with LZC-UVA lamps (kmax = 365 nm, P (power
level) = 1.7–2.2 mW cm2) and LZC-VIS UV–visible light lamps
(kmax = 400–700 nm, P = 0.27–0.29 mW cm
2). For complexes 1 and
2, irradiations in the visible region were also carried out using four green
LEDs (kmax = 525 nm, P = 0.19 mW cm
2). For complex 3,
nonirradiated controls were included, as the spectral profile of this
complex changed over time in the dark. These controls were placed in
the photoreactor but were covered in aluminum foil to avoid exposure to
light.
All irradiations were carried out at 298 K unless otherwise stated,
with spectra recorded after the following total irradiation times: 0.5, 1, 2,
3, 5, 10, 15, 20, 30, 45, 60, 90 and 120 min.
Fluorescence spectroscopy. Fluorescence spectra of the ligands Ph-
azpy, Me2N-Ph-azpy and HO-Ph-azpy, and of complexes 1–6, were
recorded at 298 K in dioxane. kex was set to the kmax for each absorption
band of the compound.
Cytotoxicity testing. Experiments to determine the cytotoxicity of 6
toward the human ovarian A2780 cancer cell line were performed
according to a previously published protocol (23). The A2780 human
ovarian cancer cell line was obtained from the ECACC (European
Collection of Cell Culture, Salisbury, UK). Cells were grown in RPMI
1640 medium with 1% 2 mM L-glutamine supplemented with 10% fetal
calf serum and 1% penicillin/streptomycin and were maintained under
standard tissue culture conditions of 310 K and 5% CO2.
After plating, human ovarian A2780 cancer cells were allowed to
grow for 48 h before addition of the complexes at concentrations ranging
from 5 to 200 lM. Solutions of the complexes were prepared in 0.5%
DMSO (v/v) to assist dissolution. Each concentration was added in tripli-
cate, and the experiment was carried out three times. Cells were exposed
to the complexes for 24 h, washed with PBS, supplied with fresh med-
ium and allowed to grow for three doubling times (72 h), and then the
protein content was measured (proportional to cell survival) using the sul-
forhodamine B (SRB) assay (24). Cisplatin was used as a positive control
(half-maximum inhibitory concentration (IC50) = 1.3  0.1 lM).
Photocytotoxicity testing. The photocytotoxicity of complex 6 toward
the HaCaT keratinocyte human skin cell line was determined by Dr Julie
Woods and Kim Robinson in a specially adapted photobiology
laboratory, with ambient light levels below 1 lux (Solatell), at the
Photobiology Unit in Ninewells Hospital, Dundee, UK. HaCaT cells
were maintained in Dulbecco’s modified Earle’s medium containing 5%
fetal bovine serum. Complexes were dissolved in Earle’s balanced salt
solution before being applied to cells. Cells were seeded at a density of
around 70 000 cells per cm2 and left to adhere overnight. After washing
cells with PBS, the test compound was added in Earle’s solution and
incubated for 1 h (310 K/5% CO2). After this time, cells were irradiated
by a bank of 2 ft 9 6 ft Cosmolux RA Plus (Cosmedico) 15 500/100 W
UVA light sources (5 J cm2, kmax = 365 nm), each filtered to attenuate
UVB and UVC wavelengths. The total irradiation time was 50 min, to
give a dose equivalent to around 15–60 min sunlight received on a
typical UK midday, and reflects the clinical conditions used for light-
activated drugs. After irradiation, the solution was removed and the cells
were thoroughly washed and returned to the incubator in complete
growth medium. Photocytotoxicity was determined 24 h later using the
neutral red uptake assay (25,26), a test designed to compare the toxicity
of a drug plus light with that of the drug alone. The amount of test
compound required to inhibit dye uptake by 50% (the IC50 value) was
determined by nonlinear regression (GraphPad Prism). Goodness of fit
was determined by the 95% confidence intervals and the R2 value.
Concentrations were added in triplicate, and each experiment was
repeated three times, using chlorpromazine as a positive control (IC50
(CPZ + UVA) = 3.6 lM).
RESULTS AND DISCUSSION
Synthesis and reactivity of Pt(II) complexes
Six Pt(II) dichlorido and diazido complexes containing three
azopyridine ligands [Pt(p-R-Ph-azpy)X2], R = H, NMe2 or OH,
X = Cl (complexes 1, 3 and 5, respectively) or N3 (complexes 2,
4 and 6, respectively) were synthesized and characterized
(Fig. 1). Pt(II) chlorido complexes of several azopyridine deriva-
tives have been reported in the literature (27,28). Using cis-[Pt
(DMSO)2Cl2] instead of [PtCl4]
2 as the starting material gave
analytically pure complexes 1 and 3 in higher yields (65–90%)
and on a shorter timescale, owing to the ease of replacement of
the two DMSO groups by incoming ligands (29). The yield was
reduced, however, in the synthesis of 5 owing to the need for an
additional purification step.
Formation of a Pt(II) azido complex is commonly carried out
by chloride extraction with silver nitrate in aqueous solution, fol-
lowed by the addition of sodium azide (30). However, the poor
aqueous solubility of the Pt(II) chlorido complexes, combined
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with the reported unsuitability of this method for Pt(II) bipyri-
dine complexes (31), led to the use of an alternative method in
this case, whereby sodium azide was added directly to the com-
plex in DMF. This approach, previously used in the synthesis of
Pt(II) azido complexes containing bipyridines (32), was found to
be equally suitable in this case, and the required complexes were
isolated in good yields.
Complex 6 was isolated as a salt in which the azopyridine
ligand was present in its deprotonated phenolate form, Na[Pt(O-
Ph-azpy)(N3)2]. Subsequent experiments indicated that the phe-
nolic OH group has a pKa of approximately 5.7 when the ligand
is coordinated to Pt(II) and that the methanolic solution of
sodium azide used in the reaction was sufficiently basic to effect
deprotonation. The presence of excess sodium azide meant that it
was not possible to isolate the protonated product by acidifying
the reaction solution during synthesis, as this would produce
hydrogen azide, an extremely toxic gas. Further attempts to iso-
late the protonated product by acidification of an aqueous solu-
tion of the isolated deprotonated sample were also unsuccessful.
Several metal complexes of HO-Ph-azpy have previously been
found to be unstable and sensitive to changes in pH (33).
The square-planar structure of [Pt(Ph-azpy)Cl2] (1) was con-
firmed by single-crystal X-ray diffraction, and corresponded well
with that previously reported (27).
We next attempted to oxidize [Pt(Ph-azpy)(N3)2] (2) to the
Pt(IV) trans-dihydroxido complex, because oxidation of Pt(II)
azido complexes has previously been found to result in strong
azide-to-Pt(IV) charge-transfer bands (6). However, reactions
with hydrogen peroxide in aqueous solution or in acetone (34)
and use of the organic oxidizing agent meta-chloroperoxybenzoic
acid were all unsuccessful, the latter appearing to decompose the
azopyridine ligand. The oxidation of [Pt(bipyridine)(N3)2] and
similar complexes is reported to be difficult to achieve, due to
the p-acceptor nature of bipyridine and its ability to stabilize
metals in their lower oxidation states (35). Ph-azpy is a stronger
p-acceptor than is bipyridine, as demonstrated by the greater sta-
bility of [Ru(Ph-azpy)2Cl2] compared with [Ru(bipyridine)2Cl2]
with respect to oxidation to Ru(III) (36). Therefore, it is perhaps
not surprising that the oxidation of 2 is not facile.
Computed geometries of Pt(II) complexes
DFT calculations showed that, upon coordination to Pt(II), the
phenyl ring of the azopyridine ligand is twisted out of the Pt–
pyridine–azo plane by between 29° and 39° in complexes 1–5.
In complex 6, however, this twist is reduced to 3° and the ligand
remains essentially planar. Selected calculated bond lengths for
complexes 1–6 are reported in Table 1. In the case of complex
1, they compare well with those from the crystal structure. In all
of the chlorido complexes (1, 3 and 5), the N=N bond (1.28–
1.29 A) of the azopyridine ligand lengthens to a similar extent
upon coordination. The Pt–Cl bonds are of a similar length
(around 2.32 A) in all complexes, despite differing ligands in the
trans position (pyridyl and aza nitrogens). In the azido com-
plexes, the N=N distances are similar to those in the chlorido
Table 1. Selected bond distances (A) of complexes 1–6 in the calculated ground-state geometries, and comparison with the X-ray crystal structure of 1.
Pt(II) chlorido complex N=N Pt–N(py) Pt–N(aza) Pt–Cl (trans-py) Pt–Cl (trans-aza)
[Pt(Ph-azpy)Cl2] (1) Calculated 1.275 2.016 2.003 2.316 2.318
[Pt(Ph-azpy)Cl2] (1) X-ray 1.291(9) 2.018(8) 1.965(8) 2.281(2) 2.288(3)
[Pt(Me2N-Ph-azpy)Cl2] (3) 1.286 2.012 2.019 2.326 2.324
[Pt(HO-Ph-azpy)Cl2] (5) 1.282 2.013 2.002 2.325 2.325
Pt(II) azido complex N=N Pt–N(py) Pt–N(aza) Pt–N3 (trans-py) Pt–N3 (trans-aza)
[Pt(Ph-azpy)(N3)2] (2) 1.280 2.021 2.019 2.002 1.989
[Pt(Me2N-Ph-azpy)(N3)2] (4) 1.289 2.017 2.049 2.012 1.995
Na[Pt(O-Ph-azpy)(N3)2] (6) 1.327 2.013 2.080 2.039 2.018
Table 2. Wavelength of maximum absorbances and extinction coeffi-




kmax (nm) e (M
1 cm1) kmax (nm) e (M
1 cm1)
Ph-azpy 222 9000 222 11 200
317 14 100 315 16 400
441 500 452 300
Me2N-Ph-azpy 273 8700 258 9100
432 29 000 418 44 300
HO-Ph-azpy† 247 8700 248 9300
357 21 600 355 22 100
1 267 7500 222 11 200
381 13 500 395 16 400
495 3200 452 3000
2 380 8700 391 9100
529 3700 566 4300
3‡ 298 4400 301 7200
602 16 000 613 19 600
647 22 000
4‡ 293 7700 298 9800
614 24 000 618 28 600
5† 272 11 000 273 12 200
475 17 000 461 18 900
481 19 800
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analogs, with the exception of complex 6 in which this bond is
approximately 0.04 A longer.
UV–visible absorption spectra of azopyridine ligands and
Pt(II) complexes
UV–visible absorption spectra of the three azopyridine ligands
and complexes 1–6 were recorded in both methanol and dioxane
(Table 2).
TD-DFT calculations were used to assign the absorption
bands of the spectra in methanol. Figure 2 shows these overlaid
with the experimental spectra for complexes 2 and 5, and
includes the EDDMs of the lowest-energy singlet transition in
each case. TD-DFT results for the other complexes and ligands
are in the Supporting Information (Tables S1 and S2, Figures S1
and S2).
The main absorption band of Ph-azpy in methanol is centered
at 317 nm, corresponding to a p–p* transition in which electron
density migrates onto the aza nitrogens. A weak band is also
seen at 441 nm in the experimental spectrum, resulting from a
formally forbidden n–p* transition. Me2N-Ph-azpy displays a
strong absorption band at 432 nm, arising from a mixed p–p*/
CT state in which charge transfer from the NMe2 group makes a
strong contribution. This results in the redshift of this band com-
pared with the purely p–p* transition of Ph-azpy. Consistent
with the r-donating ability of the para substituent on the phenyl
ring (H < OH < NMe2), a significant charge-transfer contribution
is also seen in the main transition of HO-Ph-azpy, although to a
lesser extent than in Me2N-Ph-azpy. Higher-energy absorptions
in both Me2N-Ph-azpy and HO-Ph-azpy can be ascribed to p–p*
states. Comparing the spectra of these ligands in dioxane and
methanol, the transitions display solvatochromism, as expected
from their assigned character. Although dioxane is known to
show anomalous solvatochromic effects (37), in this case the
expected trends are observed. The p–p* bands are redshifted in
the more polar methanol, because attractive polarization forces
between the solvent and the absorbing molecule lower the energy
of the excited state to a greater extent than they do the ground
state, decreasing the energy between the two. By contrast, the n–
p* transition of Ph-azpy is blueshifted in methanol; this is due to
the increased solvation of the lone pair in a more polar solvent,
decreasing the energy of the n orbital (38).
The spectrum of 1 consists of a main band centered at
381 nm, with a weaker band at lower energy. The three transi-
tions that comprise the main band all have mixed character, with
electron density migrating to the azo group and the pyridyl ring.
The formally forbidden n–p* band at lower energy is more
intense here than in the case of Ph-azpy. Complex 2 shows a dif-
ferent spectral profile. The band centered at 380 nm results from
a primarily ligand-centered transition with some contribution
from the metal, whereas a lower-energy band at 529 nm arises
from an MLCT transition with a very strong contribution from
the azido ligands.
The main absorption band of 3 arises from a ligand-centered
transition in which electron density migrates from the NMe2
region to the aza nitrogens, with only a small involvement of the
Figure 2. Left, normalized absorption spectra for azido complex 2 and chlorido complex 5 in methanol (black) and their corresponding TD-DFT spectra
(blue). Calculated singlet electronic transitions are shown as green vertical bars with heights equal to their oscillator strength. Right, EDDMs of selected
low-energy singlet electronic transitions for each complex. Electron density migrates from magenta to yellow areas.
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metal and chlorido ligands. A lesser contribution to this absorp-
tion band is made from a transition at slightly higher energy,
which is MLCT in character with a strong involvement of the
chlorido ligands. The spectrum of 4 is similar, with an asymmet-
ric band centered at 614 nm, again comprising two transitions.
Although charge transfer (from the NMe2 group to the azo nitro-
gens and the pyridyl ring) dominates the main transition, the
metal and azido groups also contribute. The second transition is
MLCT in character, with a strong contribution from the azido
groups. The relatively broad absorption band in the spectrum of
5 results from two main transitions, with two others making a
lesser contribution. The dominant transition is mixed in charac-
ter, in which electron density migrates to the azo group and pyri-
dyl ring; this is similar to that seen for 1 but in this case there is
also contribution from the OH group. The second transition is
MLCT in character, with strong involvement of the chlorido
groups. Complex 6 shows the poorest agreement between theo-
retical and experimental spectra; however, the nature of the tran-
sitions involved can still be established. It has been observed
previously that such predictions are less valid in the presence of
strongly electron-donating or electron-withdrawing groups (35);
it is assumed that the calculated energy of the orbitals is less
accurate in these cases. Three main transitions comprise the
absorption band. All are MLCT in character and have strong
contributions from the azido ligands, with charge transfer from
the oxygen involved to various extents.
The influence of the NMe2 and OH groups of complexes 3–6
can be seen by the redshift and the increased molar extinction
coefficient of the absorption bands compared with complexes 1
and 2. r-Donation from these groups decreases the p-accepting
capability of the azo group, increasing the energy of the metal-
based orbitals and therefore decreasing the energy of the MLCT
transitions. A similar decrease in energy is seen for ligand-cen-
tered transitions, owing to the increased delocalization of elec-
tron density.
Effect of pH on the absorption spectra of complexes 3 and 5
The effect of charge transfer from the NMe2 and OH groups on
the absorption properties of these complexes is demonstrated by
the UV–visible absorption spectra of complexes 3 and 5 at vary-
ing pH values (Fig. 3). At very low pH (around 0), the NMe2
group of 3 is protonated and essentially all donating ability is
lost; the solution turns from deep blue to orange and the spectral
profile resembles that of [Pt(Ph-azpy)Cl2] (1). The pKa value of
complex 3 is lower than that of the free ligand (2.11 (11)),
reflecting the greater conjugation of the nitrogen lone pair into
the p system when the ligand is coordinated to Pt(II). Similarly,
the r-donating ability of the OH group of complex 5 is greatly
enhanced upon deprotonation, as can be seen by the large red-
shift in the main absorption band. The pKa of the OH group of
this complex is around 5.7, significantly lower than that of the
free ligand (8.08). A similar effect was observed for the Ru(II)
complex [(g6-p-cymene)Ru(HO-Ph-azpy)Cl]PF6, for which the
pKa decreased to 6.48 upon coordination, and for Ir(III) Cp*
complexes, for which the pKa values range from 3.9 to 6.5 (10).
This suggests that electron density from the phenolate group is
more readily delocalized in the metal complex. Additionally, at
physiological pH (around 7.4), the complex will exist predomi-
nately in its deprotonated form, with an overall negative charge.
Fluorescence studies of Pt(II) complexes
The three azopyridine ligands and complexes 1–6 were found to
be nonemissive under the conditions used (298 K, dioxane).
Stability of Pt(II) complexes in solution and cell culture
media
The NMR spectra of complexes 1–6, recorded in acetone,
showed no change over a period of 113 days after storage at
ambient temperature in the dark. It can therefore be concluded
that these complexes are relatively stable under these conditions.
Conversely, the Au(III) complex [Au(Ph-azpy)Cl2]Cl is reported
to undergo a metal-mediated reaction to form a cationic, tricyclic
organic derivative of Ph-azpy over 12 days in an acetone solu-
tion. This cation showed higher cytotoxicity than the parent com-
plex in a number of cancer cell lines (39). Although Pt(II) is
isoelectronic and often isostructural with Au(III) (square-planar
5d8), the two display markedly different chemistries, with Au(III)
being a stronger oxidant.
The absorption spectrum of Na[Pt(O-Ph-azpy)(N3)2] (6) was
also followed over a 12-hour period in unbuffered aqueous solu-
tion (Fig. 4). The main absorption bands at around 600 nm
decreased rapidly over time, with the absorbance at 594 nm
decreasing by 16% in the six minutes after the first acquisition,
followed by the emergence of a new peak at 425 nm. The
change was also noted visually, as the intense blue color had
been lost by the end of the experiment and the solution appeared
pale gray-brown. Comparing the final spectrum with those
Figure 3. The absorption spectra of complexes 3 and 5 at different pH values.
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obtained during the pH titration experiment, it appears that the
phenolate group of 6 became protonated over time in water. This
was confirmed by the addition of 2 molar equivalents of HNO3,
after which the peak at 425 nm continued to grow and the two
peaks at around 600 nm further decreased in intensity. Con-
versely, the addition of dilute NaOH restored the spectrum to its
original profile.
Importantly, the observed rate of change is much slower than
expected, because protonation is typically instantaneous. This
reduced rate might indicate the involvement of the phenolate
group in intermolecular interactions, reducing its tendency to
protonate. Indeed, in the X-ray structures of cyclopentadienyl
Ir(III) HO/O-phenylazopyridine complexes, the phenol and
phenolate oxygens are involved in strong hydrogen bonds either
with a neighboring Ir(III) complex or to solvent (MeOH) (10).
The high stability of complex 6 in methanol also supports this
possibility. The possibility that protonation is coupled to another
slower process, such as ring-opening, is also worthy of further
investigation.
The stability of complex 6 in buffered (pH 7.3) RPMI cell cul-
ture medium was investigated to mimic the conditions used for
cytotoxicity and phototoxicity testing. A similar but much reduced
change was seen in this case (Figure S3), indicating that the com-
plex remained predominantly in its deprotonated form during these
experiments. This is supported by observations during the cell
tests, in which the blue color of the solution remained following
the 24-hour exposure of the cells to the drug.
Photoreactions of Pt(II) complexes
The photoreactions of the Pt(II) complexes 1–6 upon irradiation
with UVA and visible light were followed by UV–visible
absorption spectroscopy. Experiments were carried out in diox-
ane owing to the increased solubility in this solvent over metha-
nol, with the exception of complex 6, for which methanol was
used. Unless otherwise stated, the power levels and total irradia-
tion times were as described in the section entitled “Photoreac-
tions.”
The spectral profile of 1 remained essentially unchanged after
120 min irradiation with UVA. The main absorption band at
395 nm showed only a small decrease of 2%. This decrease con-
tinued upon prolonged irradiation, to a total of 4% after
210 min. Similarly, no change was seen after 120 min irradiation
with white light or with green light.
Irradiation with UVA resulted in a decrease in intensity of
both main bands in the absorption spectrum of the diazido com-
plex 2 (Fig. 5A). The lower-energy band (566 nm) showed the
most rapid change in absorbance, decreasing to less than half of
its initial value after 45 min. Upon further irradiation a slight
increase in intensity was seen, similar to the remainder of the
lower-energy region of the spectrum in which the absorbance
increased gradually throughout the experiment. The band at
391 nm also decreased in intensity upon irradiation throughout
the experiment. After 45 min, a new peak became apparent at
325 nm, which increased in intensity upon further irradiation. By
the end of the experiment, the sample had decolorized signifi-
cantly, from deep pink to pale brown.
Irradiation with white light also led to a decrease in intensity
of both main bands in the spectrum of 2. Similar changes in the
spectral profiles suggest that the same reaction is occurring upon
irradiation with both UVA and visible light. However, in the
case of visible light the rate of change was slower. After
120 min of irradiation, the band at 566 nm was still decreasing
in intensity and the new peak at 325 nm had not clearly
resolved. No change was seen in the spectral profile of 2 after
120 min of irradiation with green light (Figure S4).
Attempts to identify the photoproducts of these reactions were
unsuccessful. No platinum-containing species could be detected
by mass spectrometry, and the poor solubility of the complex in
many solvents suitable for irradiation experiments limited
attempts to follow the reactions by NMR. The spectrum of the
initial complex in dioxane solution showed only weak signals,
the intensities of which were rapidly lost upon irradiation. Fur-
ther work is warranted to investigate the possible production of
singlet oxygen and radicals.
Complexes 3 and 5 can be regarded as essentially stable under
the different irradiation regimes; after 120 min irradiation, no
significant changes were observed in the main absorption bands
of these complexes.
The irradiation of complex 2 with UVA light resulted in
changes to the main absorption band at 618 nm. Initially, this
band decreased in intensity with a broadening of the maxima,
and after 30 min, it began to resolve into two separate peaks.
Upon further irradiation, the peak at lower energy (621 nm)
decreased in intensity faster than that at higher energy (574 nm).
Irradiation was continued beyond 120 min, with additional spec-
tra recorded at 180 and 240 min. The trend continued, although
the intensity difference between the two peaks began to decrease.
A decrease in the higher-energy absorption band at 298 nm was
also observed. Irradiation with white light induced similar spec-
tral changes to those seen upon irradiation with UVA, although
at a slower rate. In comparison with complexes 2 and 4, rela-
tively little change was seen in the absorption spectra of azido
complex 6 upon irradiation (Fig. 5).
Attempts were made to rationalize the observed behavior con-
sidering information from the TD-DFT calculations, which pre-
dicted the nature of the transitions and the orbitals involved in
singlet excited states. Complexes 1–6 all contain an orbital with
r-antibonding character toward most of the molecule (Fig-
ure S5): LUMO + 1 for all except complex 2 (LUMO + 2). The
strong antibonding character suggests that all transitions that
























Figure 4. The change in absorption profile of 6 over a 12 h period in
unbuffered aqueous solution, indicative of the slow protonation of the
phenolate oxygen, perhaps coupled to another structural change.
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have contributions from this orbital could lead to ligand dissocia-
tion or merely to a lengthening of the appropriate bonds (40).
This could explain why none of the chlorido complexes seem to
be photoactive, despite having accessible transitions (albeit with
low probabilities) that involve the population of an antibonding
orbital. In the case of the azido complexes, dissociation may be
more probable. The azido group is known to display a rich pho-
tochemistry, involving the generation of nitrenes and azidyl radi-
cals among other species (41,42), both of which could induce
further reaction or decomposition of the photoproducts.
Complex 2 is the most photoactive of the three azido com-
plexes. The strongest predicted transition in this complex
(386 nm, with an oscillator strength f of 0.42) has a small (9%)
contribution from a HOMO ? LUMO + 2 transition, corre-
sponding to population of this strongly antibonding orbital. An
additional transition at 372 nm has a much smaller oscillator
strength (f = 0.08) but a large contribution from the
HOMO ? LUMO + 2 transition (59%), and is also likely to be
significant.
The changes in spectral profile of 2 are similar upon irradia-
tion with UVA or visible light, although occur at a slower rate
in the case of the latter. The transitions around 386 nm and
372 nm could potentially be accessed by the visible light source
used, as its output spectrum shows spikes of intensity in this
region. The energy of the green LEDs (kmax = 525 nm) was
insufficient to induce dissociative transitions and resulted in no
change to the absorption spectrum of 2. Because LUMO + 2 is
r-antibonding toward most of the bonds in the molecule, it is
likely that dissociation of the complex is extensive. The loss of
the intense color and the rapid decrease in signal intensity in
both the absorption and the NMR spectra are consistent with sig-
nificant decomposition. However, elucidation of the photoprod-
ucts may be difficult even if dissociation is less extensive. For
example, were free azopyridine to be released it would undergo
cis–trans isomerization upon irradiation, resulting in changes to
the spectral profile that would hinder its identification. According
to computational data, similar considerations can be made for
complexes 4 and 6.
Cytotoxicity and photocytotoxicity of complex 6
The cytotoxicity of several Ru(II) complexes of azopyridines has
been reported (11), as well as that of an Au(III) Ph-azpy com-
plex (39). Reports on the cytotoxicity of Pt(II) azopyridine com-
plexes are scarce; however, Chakravarty et al. (12) found that
[Pt(Ph-azpy)(an-cat)] showed remarkable light-induced cytotoxic-
ity in HaCaT and MCF-7 cells, with IC50 values 10-fold lower
after irradiation with visible light (400–700 nm) than in the dark.
It was suggested that the photoinduced cytotoxicity of these
complexes could be associated with reduction of the coordinated
azo bond of Ph-azpy by intracellular glutathione, triggering the
release of the catecholate ligand.
The lack of aqueous solubility of the complexes synthesized
here limited cell testing of all but complex 6, which is reason-
ably water soluble due to its isolation as a sodium salt. Complex
6 was tested against the A2780 human ovarian cancer cell line,
showing moderate cytotoxicity with an IC50 value of
67.7  8.9 lM upon exposure to the cells for 24 h. It is note-
worthy that, although the complex remains predominately depro-
tonated in cell culture media, it may become protonated upon
uptake into certain organelles—such as lysosomes—in which the
pH is lower.
Encouraged by the cytotoxicity and photoactivity data, com-
plex 6 was tested for photocytotoxicity toward immortalized
HaCaT keratinocytes. The experiments were carried out as
described in the section “Photocytotoxicity testing”, that is, incu-
bation of the cells with the complex for 1 h, followed by 50 min
of UVA irradiation. The cytotoxic effect exerted by this complex
was stronger upon irradiation with UVA light (IC50 = 72.1 lM)
than in the dark (sham-irradiated control; IC50 = 112.9 lM),
Figure 5. UV–visible absorption spectra of diazido complexes 2, 4 and 6 after irradiation with (A) UVA and (B) visible white light, over 120 min in
dioxane.
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indicating a 36% increase in the cytotoxicity of 6 upon UVA
irradiation.
During testing, it was observed that the intense blue color of
the complex caused staining of the cells, and thus provided a
means of visualizing the complex within the cells. This staining
was evident in the majority of cells in the sample, estimated at
around 80% by visual inspection (data not shown). Following
the 1 h incubation period prior to irradiation, the blue color
appeared to be localized in the nuclear region, with only punctate
staining of the cytoplasm (Figure S6). This suggests that the
platinum complex reaches the nucleus, because the ligand alone
does not give rise to a blue solution, and that uptake into the
nucleus is rapid.
Several observations during the testing of this complex war-
rant further investigation. The punctate staining in the cytoplasm
could result from accumulation in mitochondria as well as in the
nucleus, indicating a possible targeting of cellular DNA.
CONCLUSIONS
UV–visible absorption spectra of Pt(II) chlorido complexes of
azopyridine ligands showed very little change upon irradiation
with UVA and visible light. However, the Pt(II) azido complexes
2 and 4 were found to be photoactive in both cases, with dissoci-
ation likely induced by population of a r-antibonding orbital.
Although complex 2 showed similar changes upon irradiation
with both UVA and visible light, complex 4 showed differing
behavior between the two; it is likely that different transitions
were induced in each case, giving rise to different photoproducts.
Complex 6 showed some photoactivity upon irradiation with
UVA light, but very little was observed with visible light. This
complex showed moderate cytotoxicity against the human ovar-
ian A2780 cancer cell line (IC50 = 67.7 lM). It was also cyto-
toxic toward HaCaT keratinocytes, and its activity increased
upon irradiation with UVA light, with IC50 values of 112.9 lM
in the dark and 72.1 lM after irradiation. This complex was
found to stain treated cells blue, enabling its location within the
cells to be visualized without labeling.
One aim of this work was to synthesize Pt(II) azido com-
plexes with ligands that exhibit strong absorbance in the visible
region, to investigate whether this would lead to photoactivity
upon irradiation at these wavelengths. As well as strong absor-
bance in the visible region, these complexes have a large scope
for design by, for example, changing the substituents on the
phenyl ring, which has been shown here to have a considerable
influence on their properties. These results therefore suggest
that further exploration of the use of ligands that absorb
strongly in the visible region may lead to successful attempts
to increase the wavelength of photoactivation of platinum azido
complexes.
ACKNOWLEDGEMENTS—We thank the MRC (grant number
G0701062), EPSRC (grant numbers EP/G006792 and EP/F034210/1) and
EU FP7 (grant number 20377; MC fellowship for LS). LS acknowledges
the Severo Ochoa Centres of Excellence Program of the Spanish State
Research Agency (grant number CEX2018-000867-S; DIPC) for funding
and the Spanish Multi-MetDrugs network (RED2018-102471-T) for
fruitful discussion. AMP acknowledges funding from the MINECO of
Spain (SEV-2016-0686 and CTQ2017-84932-P). We also thank Dr Julie
Woods and Kim Robinson (University of Dundee) for phototoxicity
testing, and Dr Lijiang Song and Dr Ivan Prokes (University of
Warwick) for help with MS and NMR, respectively.
SUPPORTING INFORMATION
Additional supporting information may be found online in the
Supporting Information section at the end of the article:
Table S1. Calculated singlet electronic transitions for azopy-
ridine ligands in methanol.
Table S2. Calculated singlet electronic transitions for com-
plexes 1–6 in methanol.
Figure S1. Normalized absorption spectra of azopyridine
ligands in methanol and their corresponding TD-DFT spectra,
and EDDMs of selected low-energy singlet electronic transitions
for each ligand.
Figure S2. Normalized absorption spectra for complexes 1, 3,
4 and 6 in methanol and their corresponding TD-DFT spectra.
Figure S3. The change in absorption profile of complex 6
over a 12 h period in cell culture medium.
Figure S4. UV–visible absorption spectra of complex 2 fol-
lowing irradiation with green light over 120 min in dioxane.
Figure S5. Selected orbitals of Pt(II) azopyridine complexes.
Figure S6. A microscope image of HaCaT cells prior to irra-
diation, 1 h after addition of complex 6.
REFERENCES
1. McFarland, S. A., A. Mandel, R. Dumoulin-White and G. Gasser
(2020) Metal-based photosensitizers for photodynamic therapy: The
future of multimodal oncology? Curr. Opin. Chem. Biol. 56, 23–27.
2. Monro, S., K. L. Colon, H. Yin, J. Roque III, P. Konda, S. Gujar,
R. P. Thummel, L. Lilge, C. G. Cameron and S. A. McFarland
(2019) Transition metal complexes and photodynamic therapy from a
tumor-centered approach: Challenges, opportunities, and highlights
from the development of TLD1433. Chem. Rev. 119, 797–828.
3. Imberti, C., P. Zhang, H. Huang and P. J. Sadler (2020) New
designs for phototherapeutic transition metal complexes. Angew.
Chem. Int. Ed. 59, 61–73.
4. Shi, H. and P. J. Sadler (2020) How promising is phototherapy for
cancer? Br. J. Cancer 123, 871–873.
5. Bednarski, P. J., F. S. Mackay and P. J. Sadler (2007) Photoactivat-
able platinum complexes. Anticancer Agents Med. Chem. 7, 75–93.
6. Venkatesh, V. and P. J. Sadler (2018) Platinum(IV) prodrugs. Met.
Ions Life Sci. 18, 69–107.
7. Shi, H., C. Imberti and P. J. Sadler (2019) Diazido platinum(IV)
complexes for photoactivated anticancer chemotherapy. Inorg. Chem.
Front. 6, 1623–1638.
8. Needham, R. J., C. Sanchez-Cano, X. Zhang, I. Romero-Canelon, A.
Habtemariam, M. S. Cooper, L. Meszaros, G. J. Clarkson, P. J.
Blower and P. J. Sadler (2017) In-cell activation of organo-osmium
(II) anticancer complexes. Angew. Chem. Int. Ed. 56, 1017–1020.
9. Zhang, X., F. Ponte, E. Borfecchia, A. Martini, C. Sanchez-Cano, E.
Sicilia and P. J. Sadler (2019) Glutathione activation of an
organometallic half-sandwich anticancer drug candidate by ligand
attack. Chem. Commun. 55, 14602–14605.
10. Zhang, W.-Y., S. Banerjee, G. M. Hughes, H. E. Bridgewater, J.-I.
Song, B. Breeze, G. J. Clarkson, J. P. C. Coverdale, C. Sanchez-
Cano, F. Ponte, E. Sicilia and P. J. Sadler (2020) Ligand-centred
redox activation of inert organoiridium anticancer catalysts. Chem.
Sci. 11, 5466–5480.
11. Dougan, S. J., M. Melchart, A. Habtemariam, S. Parsons and P. J.
Sadler (2006) Phenylazo-pyridine and phenylazo-pyrazole chlorido
ruthenium(II) arene complexes: Arene loss, aquation and cancer cell
cytotoxicity. Inorg. Chem. 45, 10882–10894.
Photochemistry and Photobiology 9
12. Mitra, K., S. Patil, P. Kondaiah and A. R. Chakravarty (2015) 2-
(Phenylazo)pyridineplatinum(II) catecholates showing photocytotoxi-
city, nuclear uptake, and glutathione-triggered ligand release. Inorg.
Chem. 54, 253–264.
13. Dougan, S. J., A. Habtemariam, S. E. McHale, S. Parsons and P. J.
Sadler (2008) Catalytic organometallic anticancer complexes. Proc.
Natl Acad. Sci. USA 105, 11628–11633.
14. Price, J. H., A. N. Williamson, R. F. Schramm and G. B. Wayland
(1972) Palladium(II) and platinum(II) alkyl sulfoxide complexes.
Examples of sulfur-bonded, mixed sulfur- and oxygen-bonded, and
totally oxygen-bonded complexes. Inorg. Chem. 11, 1280–1284.
15. Frisch, M. J., G. W. Trucks, H. B. Schlegel, G. E. Scuseria, M. A.
Robb, J. R. Cheeseman, J. A. Jr Montgomery, T. Vreven, K. N.
Kudin, J. C. Burant, J. M. Millam, S. S. Iyengar, J. Tomasi, V. Bar-
one, B. Mennucci, M. Cossi, G. Scalmani, N. Rega, G. A. Petersson,
H. Nakatsuji, M. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hase-
gawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, M.
Klene, X. Li, J. E. Knox, H. P. Hratchian, J. B. Cross, V. Bakken,
C. Adamo, J. Jaramillo, R. Gomperts, R. E. Stratmann, O. Yazyev,
A. J. Austin, R. Cammi, C. Pomelli, J. W. Ochterski, P. Y. Ayala,
K. Morokuma, G. A. Voth, P. Salvador, J. J. Dannenberg, V. G.
Zakrzewski, S. Dapprich, A. D. Daniels, M. C. Strain, O. Farkas, D.
K. Malick, A. D. Rabuck, K. Raghavachari, J. B. Foresman, J. V.
Ortiz, Q. Cui, A. G. Baboul, S. Clifford, J. Cioslowski, B. B. Ste-
fanov, G. Liu, A. Liashenko, P. Piskorz, I. Komaromi, R. L. Martin,
D. J. Fox, T. Keith, M. A. Al-Laham, C. Y. Peng, A. Nanayakkara,
M. Challacombe, P. M. W. Gill, B. Johnson, W. Chen, M. W.
Wong, C. Gonzalez and J. A. Pople (2004) Gaussian 03, (Revision
D 0.1), Gaussian Inc.
16. Perdew, J. P., K. Burke and M. Ernzerhof (1996) Generalized gradi-
ent approximation made simple. Phys. Rev. Lett. 77, 3865–3868.
17. Hay, P. J. and W. R. Wadt (1985) Ab initio effective core potentials
for molecular calculations. Potentials for the transition metal atoms
Sc to Hg. J. Chem. Phys. 82, 270–283.
18. McLean, A. D. and G. S. Chandler (1980) Contracted Gaussian basis
sets for molecular calculations. I. Second row atoms, Z=11–18. J.
Chem. Phys. 72, 5639–5648.
19. Casida, M. E., C. Jamorski, K. C. Casida and D. R. Salahub (1998)
Molecular excitation energies to high-lying bound states from time-
dependent density-functional response theory: Characterization and
correction of the time-dependent local density approximation ioniza-
tion threshold. J. Chem. Phys. 108, 4439–4449.
20. Cossi, M., N. Rega, G. Scalmani and V. Barone (2003) Energies,
structures, and electronic properties of molecules in solution with the
C-PCM solvation model. J. Comput. Chem. 24, 669–681.
21. Browne, W. R., N. M. O’Boyle, J. J. McGarvey and J. G. Vos
(2005) Elucidating excited state electronic structure and intercompo-
nent interactions in multicomponent and supramolecular systems.
Chem. Soc. Rev. 34, 641–663.
22. O’Boyle, N. M. and J. G. Vos (2005) GaussSum, Dublin City
University. Available at http://gausssum.sourceforge.net
23. Aird, R. E., J. Cummings, A. A. Ritchie, M. Muir, R. E. Morris, H.
Chen, P. J. Sadler and D. I. Jodrell (2002) In vitro and in vivo activ-
ity and cross resistance profiles of novel ruthenium(II) organometal-
lic arene complexes in human ovarian cancer. Br. J. Cancer 86,
1652–1657.
24. Vichai, V. and K. Kirtikara (2006) Sulforhodamine B colorimetric
assay for cytotoxicity screening. Nat. Protoc. 1, 1112–1116.
25. Borenfreund, E. and J. A. Puerner (1985) Toxicity determined
in vitro by morphological alterations and neutral red absorption. Tox-
icol. Lett. 24, 119–124.
26. Traynor, N. J., P. E. Beattie, S. H. Ibbotson, H. Moseley, J. Fergu-
son and J. A. Woods (2005) Photogenotoxicity of hypericin in
HaCaT keratinocytes: implications for St. John’s Wort supplements
and high dose UVA-1 therapy. Toxicol. Lett. 158, 220–224.
27. Rauth, G. K., S. Pal, D. Das, S. Chittaranjan, A. M. Z. Slawin and
J. D. Woollins (2001) Synthesis, spectral characterization and elec-
trochemical studies of mixed-ligand complexes of platinum(II) with
2-(arylazo)pyridines and catechols. Single-crystal X-ray structure of
dichloro{2-(phenylazo) pyridine}platinum(II). Polyhedron 20, 363–
372.
28. Panda, M., S. Das, G. Mostafa, A. Casti~neiras and S. Goswami
(2005) Platinum complexes of diazoligands. Studies of regioselective
aromatic ring amination, oxidative halogen addition and reductive
halogen elimination reactions. Dalton Trans. 1249–1255.
29. Rochon, F. F., C. Bensimon and C. Tessier (2008) Multinuclear
magnetic resonance study of Pt(II) compounds with sulfoxide ligands
and crystal structures of complexes of the types [Pt(R2SO)X3]
 and
Pt(R2SO)2Cl2. Inorg. Chim. Acta 361, 16–28.
30. Muller, P., B. Schroder, J. Parkinson, N. Kratochwil, R. A. Coxall,
A. Parkin, S. Parsons and P. J. Sadler (2003) Nucleotide cross-link-
ing induced by photoreactions of platinum(IV)–azide complexes.
Angew. Chem. Int. Ed. 42, 335–339.
31. Wimmer, S., P. Castan, F. L. Wimmer and N. P. Johnson (1998)
Aqueous chemistry of Pt(II) and Pd(II) complexes of 2,20-bipyridine
and 1,10-phenanthroline: pH dependence. Inorg. Chim. Acta 142,
13–15.
32. Kamath, S. S., V. Uma and T. S. Srirastava (1989) Spectroscopic
and electrochemical studies of some a-diimine complexes of plat-
inum(II) and palladium(II) with azide and chloride. Inorg. Chim.
Acta 161, 49–56.
33. Anderson, R. G. and G. Nickless (1967) Metal complexes of some
azo and azomethine dyestuffs: Part III. Metal complexes of 2-(2-
pyridylazo)phenol and 4-(2-pyridylazo) phenol. Anal. Chim. Acta 39,
469–477.
34. Ghedini, M., D. Pucci, A. Crispini and G. Barberio (1999) Oxidative
addition to cyclometalated azobenzene platinum(II) complexes: a
route to octahedral liquid crystalline materials. Organometallics 18,
2116–2124.
35. Salassa, L., C. Garino, A. Albertino, G. Volpi, C. Nervi, R. Gobetto
and K. I. Hardcastle (2008) Computational and spectroscopic studies
of new rhenium(I) complexes containing pyridylimidazo[1,5-a]pyri-
dine ligands: charge transfer and dual emission by fine-tuning of
excited states. Organometallics 27, 1427–1435.
36. Krause, R. A. and K. Krause (1980) Chemistry of bipyridyl-like
ligands. Isomeric complexes of ruthenium(II) with 2-(phenylazo) pyr-
idine. Inorg. Chem. 19, 2600–2603.
37. Suppan, P. and N. M. Ghoneim (1997) Solvatochromism. Royal
Society of Chemistry, Cambridge.
38. Lambert, J. B., H. F. Shurvell, D. A. Lightner and R. G. Cooks
(1998) Organic Structural Spectroscopy. Prentice-Hall, New Jersey.
39. Garza-Ortiz, A., H. den Dulk, J. Brouwer, K. Jaap, S. Huub, A. L.
Spek and J. Reedijk (2007) The synthesis, chemical and biological
properties of dichlorido(azpy)gold(III) chloride (azpy = 2-(pheny-
lazo)pyridine) and the gold-induced conversion of the azpy ligand to
the chloride of the novel tricyclic pyrido[2,1-c][1,2,4]benzotriazin-
11-ium cation. J. Inorg. Biochem. 101, 1922–1930.
40. Garino, C. and L. Salassa (2013) The photochemistry of transition
metal complexes using DFT. Phil. Trans. R. Soc. A 371, 20120134.
41. Sima, J. (2006) Photochemistry of azide-moiety containing inorganic
compounds. Coord. Chem. Rev. 250, 2325–2334.
42. Ruggiero, E., S. Alonso-de Castro, A. Habtemariam and L. Salassa
(2014) The photochemistry of transition metal complexes and its
application in biology and medicine. In: Luminescent and photoac-
tive transition metal complexes as biomolecular probes and cellular
reagents. Structure and Bonding, Vol. 165 (edited by K. W. Lo),
Springer, Berlin, Heidelberg.
10 Sarah J. Farley et al.
